Gastrointestinal Adverse Events of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis

Diabetes Technology and Therapeutics - United States
doi 10.1089/dia.2014.0188
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Mary Ann Liebert Inc

Related search

The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis

PLoS ONE
Multidisciplinary
2015English

Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: A Systematic Review and Mixed-Treatment Comparison Analysis

Diabetes, Obesity and Metabolism
Internal MedicineEndocrinologyMetabolismDiabetes
2017English

Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT-2is) and Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Patients With Type 2 Diabetes: A Systematic Review and Network Meta-Analysis Study Protocol

BMJ Open
Medicine
2018English

Glucagon-Like Peptide 1 Receptor Agonists: A New Approach to Type 2 Diabetes Management

South African Family Practice
2013English

Correction To: Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Their Use and Differential Features

Clinical Drug Investigation
MedicinePharmacology
2020English

Review of Glucagon‐Like Peptide‐1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in Patients With Chronic Kidney Disease and Their Renal Effects

Journal of Diabetes
EndocrinologyMetabolismDiabetes
2019English

A Review of Practical Issues on the Use of Glucagon-Like Peptide-1 Receptor Agonists for the Management of Type 2 Diabetes

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2018English

Pdb112 - Treatment and Dosing Patterns Among Patients With Type 2 Diabetes (T2d) Initiating Glucagon-Like Peptide-1 Receptor Agonists (Glp-1 Ras) in Several Countries

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Glucagon-Like Peptide-1 Receptor Agonists for Type 2 Diabetes: A Comprehensive Review of How to Weigh the Options, Select the Right Patients, and Maximize Benefits

Endocrine Practice
MedicineEndocrinologyMetabolismDiabetes
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy